Miraqules will showcase its blood clotting technology at TechCrunch Disrupt 2025

Miracles Co-founder and CEO Sabir Hussain always knew he wanted to follow in his father’s footsteps and run his own business. But he never thought he’d be launching a biotech company built around a technology that would be able to help his father after a near-fatal accident left him nearly bleeding to death years ago.

Bangalore-based Miracles has developed a nanotechnology in powder form that mimics blood clotting proteins. Blood clotting powders rapidly form fibrous compounds at room temperature that have a high dosage ratio and can quickly absorb into the blood when applied.

“It’s a product that gives you an immediate response,” Hussain told TechCrunch. “If a person is bleeding, you apply it, and the bleeding stops. This whole thing happens in a minute or two.”

Miraculous Top 20 Startup battlefield This technology will be presented in the final and stage TechCrunch Disrupt 2025This week in San Francisco.

Hossain said he developed the technology almost by accident.

He went to grad school for biomedical engineering and began working in a research lab focused on biomaterials where his job was essentially to simulate the work of a doctoral student.

“I was actually pretty bad,” Hussain said. “His job was to create 3D structures that would help grow bone tissue, which could help build bone. Every time I was synthesizing that material, it was falling apart.”

One day he took the broken particles and crushed them. He brought this powder to a group working on blood clotting who were struggling to properly mix their solution to see if it might help — and it did.

“It was probably a whole blood clot within five to 10 seconds. I ran to my professor and from then on we started thinking about what happened,” Hussain said. “We have come up with a completely new process of combining off-the-shelf materials into a nanomaterial that mimics blood clotting proteins.”

Hussain then teamed up with his childhood friend Mubin Midda and they began trying to develop the technology so that it could be taken out of the lab – with as little funding as possible.

Since then, the company has managed to secure 11 patents in seven different countries, including India, the United States and Israel.

Miracles’ technology is already being piloted in a trauma care center in India and the company expects to receive its regulatory clearance in India within the next few months. It is on track to receive clearance from the US Food and Drug Administration in 2026.

“One thing we did from the beginning, we went directly to the US FDA, there’s something called pre-submission. We tried to get their feedback on what we needed to do to get this product approved, which helped us a lot.”

The company reached these milestones having raised less than $700,000 in capital, largely from grants.

Miracles is looking to ramp up deployments and pilot programs over the next year. It has already received potential interest from 10 different hospital chains in India and the Israeli Defense Forces.

If you want to learn from Miracles, and watch dozens of additional pitches, attend valuable workshops, and make connections that drive business results, Go here to learn more about this year’s disruptionHeld in San Francisco from October 27 to 29.